After Cardiovascular Disease, Novartis’ Rare Disease Drug Flops in Late-Stage Lung Cancer Study
Novartis has been laboring around for the last few years to expand the market for Ilaris, an anti-inflammatory drug that’s currently approved to treat a few rare inflammatory indications, but …
Read More